JP7123074B2 - マイコバクテリア感染の処置において使用するためのサンフェトリネム、その塩、またはそのエステル - Google Patents

マイコバクテリア感染の処置において使用するためのサンフェトリネム、その塩、またはそのエステル Download PDF

Info

Publication number
JP7123074B2
JP7123074B2 JP2019561315A JP2019561315A JP7123074B2 JP 7123074 B2 JP7123074 B2 JP 7123074B2 JP 2019561315 A JP2019561315 A JP 2019561315A JP 2019561315 A JP2019561315 A JP 2019561315A JP 7123074 B2 JP7123074 B2 JP 7123074B2
Authority
JP
Japan
Prior art keywords
compound
mycobacterium
tuberculosis
pharmaceutically acceptable
ester prodrug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019561315A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020519592A (ja
JP2020519592A5 (https=
Inventor
ダビド、バロス、アギーレ
ロバート、エイチ．ベーツ
ルーベン、ゴンザレス、デル、リオ
アルフォンソ、メンドーサ、ロサーナ
サンティアゴ、ラモン、ガルシア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of JP2020519592A publication Critical patent/JP2020519592A/ja
Publication of JP2020519592A5 publication Critical patent/JP2020519592A5/ja
Application granted granted Critical
Publication of JP7123074B2 publication Critical patent/JP7123074B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D463/00—Heterocyclic compounds containing 1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D463/10—Heterocyclic compounds containing 1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D463/12—Heterocyclic compounds containing 1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals attached in position 7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019561315A 2017-05-08 2018-05-04 マイコバクテリア感染の処置において使用するためのサンフェトリネム、その塩、またはそのエステル Active JP7123074B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17382255 2017-05-08
EP17382255.2 2017-05-08
PCT/EP2018/061615 WO2018206466A1 (en) 2017-05-08 2018-05-04 Sanfetrinem or a salt or ester thereof for use in treating mycobacterial infection

Publications (3)

Publication Number Publication Date
JP2020519592A JP2020519592A (ja) 2020-07-02
JP2020519592A5 JP2020519592A5 (https=) 2021-06-17
JP7123074B2 true JP7123074B2 (ja) 2022-08-22

Family

ID=58709903

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019561315A Active JP7123074B2 (ja) 2017-05-08 2018-05-04 マイコバクテリア感染の処置において使用するためのサンフェトリネム、その塩、またはそのエステル

Country Status (22)

Country Link
US (1) US11253500B2 (https=)
EP (1) EP3621609B1 (https=)
JP (1) JP7123074B2 (https=)
KR (1) KR102575872B1 (https=)
CN (1) CN110869016B (https=)
AU (1) AU2018265192B2 (https=)
BR (1) BR112019023322B1 (https=)
CA (1) CA3060396A1 (https=)
CY (1) CY1125546T1 (https=)
DK (1) DK3621609T3 (https=)
ES (1) ES2925215T3 (https=)
HR (1) HRP20221212T1 (https=)
HU (1) HUE059818T2 (https=)
LT (1) LT3621609T (https=)
PL (1) PL3621609T3 (https=)
PT (1) PT3621609T (https=)
RS (1) RS63461B1 (https=)
RU (1) RU2757272C2 (https=)
SI (1) SI3621609T1 (https=)
SM (1) SMT202200400T1 (https=)
WO (1) WO2018206466A1 (https=)
ZA (1) ZA201906810B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111184718A (zh) * 2018-11-15 2020-05-22 鲁南制药集团股份有限公司 法罗培南在制备治疗初治病原学阳性肺结核药物中的用途
CN117462551B (zh) * 2023-12-27 2024-05-17 深圳国家感染性疾病临床医学研究中心 茚地那韦和/或其衍生物在制备抗结核药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016046845A1 (en) 2014-09-25 2016-03-31 Manu Chaudhary Stealth, targeted nanoparticles (stn) for oral drug delivery

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ435990A3 (cs) 1989-09-08 1999-11-17 Glaxo S.P.A. Kyselina 10-(1-hydroxyethyl)-11-oxo-1-azatricyklo/7,2,0,03,8/-undec-2en-2-karboxylová a její deriváty, způsob jejich výroby, použití pro výrobu farmaceutických prostředků a farmaceutické prostředky s jejich obsahem
GB9018330D0 (en) * 1990-08-21 1990-10-03 Glaxo Spa Heterocyclic compounds
JP3151215B2 (ja) 1990-08-21 2001-04-03 グラクソ・ソシエタ・ペル・アツイオーニ 複素環式化合物
GB9104769D0 (en) 1991-03-07 1991-04-17 Glaxo Spa Heterocyclic compounds
GB9305813D0 (en) 1993-03-20 1993-05-05 Glaxo Spa Chemical process
EP2085084A1 (en) * 2008-01-29 2009-08-05 LEK Pharmaceuticals D.D. Use of inhibitor of beta-lactamases and its combination with beta-lactam antibiotics
EP2135871A1 (en) * 2008-06-18 2009-12-23 LEK Pharmaceuticals D.D. New trinem antibiotics and inhibitors of beta-lactamases
MA41494B1 (fr) * 2015-02-12 2020-10-28 Glaxosmithkline Ip No 2 Ltd Composés benzoxaborole substitués en position 4 et utilisations associées

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016046845A1 (en) 2014-09-25 2016-03-31 Manu Chaudhary Stealth, targeted nanoparticles (stn) for oral drug delivery

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Antimicrobial Agents and Chemotherapy，1996年，Vol.40, No.9，pp.2142-2146
Clinical Microbiology and Infection，1997年，Vol.3, Supplement 2，p.169, P706
International Journal of Systematic Bacteriology，1995年，Vol.45, No.4，pp.724-728
Kekkaku，1982年，Vol.57, No.8，pp.409-417

Also Published As

Publication number Publication date
ES2925215T3 (es) 2022-10-14
RU2019139864A (ru) 2021-06-09
WO2018206466A1 (en) 2018-11-15
US20200289462A1 (en) 2020-09-17
EP3621609A1 (en) 2020-03-18
JP2020519592A (ja) 2020-07-02
AU2018265192B2 (en) 2021-06-17
KR20200003816A (ko) 2020-01-10
BR112019023322B1 (pt) 2023-11-14
CA3060396A1 (en) 2018-11-15
CY1125546T1 (el) 2026-02-25
BR112019023322A2 (pt) 2020-06-16
ZA201906810B (en) 2021-03-31
US11253500B2 (en) 2022-02-22
EP3621609B1 (en) 2022-07-27
HRP20221212T1 (hr) 2022-12-09
SI3621609T1 (sl) 2022-10-28
PT3621609T (pt) 2022-08-24
AU2018265192A1 (en) 2019-11-07
PL3621609T3 (pl) 2022-11-14
SMT202200400T1 (it) 2022-11-18
DK3621609T3 (da) 2022-08-29
RU2757272C2 (ru) 2021-10-12
CN110869016B (zh) 2023-09-12
HUE059818T2 (hu) 2022-12-28
CN110869016A (zh) 2020-03-06
RS63461B1 (sr) 2022-08-31
RU2019139864A3 (https=) 2021-06-28
KR102575872B1 (ko) 2023-09-08
LT3621609T (lt) 2022-10-10

Similar Documents

Publication Publication Date Title
Perna et al. Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance
Dutta et al. Mycobacterial protein tyrosine phosphatases A and B inhibitors augment the bactericidal activity of the standard anti-tuberculosis regimen
ES2306146T3 (es) Uso de derivados de quinolina sustituidos para el tratamiento de enfermedades micobacterianas resistentes a farmacos.
Nuermberger et al. Current development and future prospects in chemotherapy of tuberculosis
ES2905413T3 (es) Compuestos tricíclicos de benzoxaborol y usos de los mismos
Protopopova et al. In search of new cures for tuberculosis
JP7123074B2 (ja) マイコバクテリア感染の処置において使用するためのサンフェトリネム、その塩、またはそのエステル
JP2018506538A5 (https=)
WO2015126930A2 (en) Booster drug therapy for mycobacterium infections
TW202038947A (zh) 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑
Zhang et al. Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice
Sano et al. Comparative in vitro and in vivo antimicrobial activities of sitafloxacin, gatifloxacin and moxifloxacin against Mycobacterium avium
CN113164456A (zh) 使用四环素化合物治疗分枝杆菌感染的方法
AU2017237380B2 (en) Antituberculosis agent
WO2023207398A1 (zh) 一种抗特发性肺纤维化药物尼达尼布在结核病治疗中的应用
JP2015536949A (ja) 細菌感染症のための抗生物質を用いる方法および組成物
TW201632177A (zh) 有效對抗包括抗藥性微生物類之微生物群的組合治療
JP2020519592A5 (https=)
Alotaibi Study of drug interaction, mutant frequency and mutant prevention concentration of DFMBT against Mycobacterium tuberculosis H37RV
WO2018019031A1 (en) A pharmaceutical composition comprising an ionophore and a beta-lactam antibiotic and use thereof
CA3159637A1 (en) Ror gamma t inhibitors and topical uses thereof
US12565474B2 (en) Discovery, total synthesis, and bioactivity of doscadenamides
RU2831120C2 (ru) Способы лечения микобактериальных инфекций с применением тетрациклиновых соединений
CN120379693A (zh) 一种药物组合及应用
CN120661516A (zh) 毛壳素或其衍生物在制备药物中的应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210426

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210426

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220427

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220712

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220809

R150 Certificate of patent or registration of utility model

Ref document number: 7123074

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250